235 related articles for article (PubMed ID: 27027731)
21. A novel orally available seleno-purine molecule suppresses triple-negative breast cancer cell proliferation and progression to metastasis by inducing cytostatic autophagy.
Chang CH; Bijian K; Wernic D; Su J; da Silva SD; Yu H; Qiu D; Asslan M; Alaoui-Jamali MA
Autophagy; 2019 Aug; 15(8):1376-1390. PubMed ID: 30773992
[TBL] [Abstract][Full Text] [Related]
22. Energy balance modulates mouse skin tumor promotion through altered IGF-1R and EGFR crosstalk.
Moore T; Beltran L; Carbajal S; Hursting SD; DiGiovanni J
Cancer Prev Res (Phila); 2012 Oct; 5(10):1236-46. PubMed ID: 22896210
[TBL] [Abstract][Full Text] [Related]
23. Enhanced therapeutic effect of multiple injections of HSV-TK + GCV gene therapy in combination with ionizing radiation in a mouse mammary tumor model.
Vlachaki MT; Chhikara M; Aguilar L; Zhu X; Chiu KJ; Woo S; Teh BS; Thompson TC; Butler EB; Aguilar-Cordova E
Int J Radiat Oncol Biol Phys; 2001 Nov; 51(4):1008-17. PubMed ID: 11704325
[TBL] [Abstract][Full Text] [Related]
24. Radiation-induced lung metastasis development is MT1-MMP-dependent in a triple-negative breast cancer mouse model.
Bouchard G; Therriault H; Geha S; Bujold R; Saucier C; Paquette B
Br J Cancer; 2017 Feb; 116(4):479-488. PubMed ID: 28103615
[TBL] [Abstract][Full Text] [Related]
25. Pharmacological activation of estrogen receptor beta augments innate immunity to suppress cancer metastasis.
Zhao L; Huang S; Mei S; Yang Z; Xu L; Zhou N; Yang Q; Shen Q; Wang W; Le X; Lau WB; Lau B; Wang X; Yi T; Zhao X; Wei Y; Warner M; Gustafsson JÅ; Zhou S
Proc Natl Acad Sci U S A; 2018 Apr; 115(16):E3673-E3681. PubMed ID: 29592953
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of in vivo breast cancer growth by antisense oligodeoxynucleotides to type I insulin-like growth factor receptor mRNA involves inactivation of ErbBs, PI-3K/Akt and p42/p44 MAPK signaling pathways but not modulation of progesterone receptor activity.
Salatino M; Schillaci R; Proietti CJ; Carnevale R; Frahm I; Molinolo AA; Iribarren A; Charreau EH; Elizalde PV
Oncogene; 2004 Jul; 23(30):5161-74. PubMed ID: 15122317
[TBL] [Abstract][Full Text] [Related]
27. Transforming growth factor-β, insulin-like growth factor I/insulin-like growth factor I receptor and vascular endothelial growth factor-A: prognostic and predictive markers in triple-negative and non-triple-negative breast cancer.
Bahhnassy A; Mohanad M; Shaarawy S; Ismail MF; El-Bastawisy A; Ashmawy AM; Zekri AR
Mol Med Rep; 2015 Jul; 12(1):851-64. PubMed ID: 25824321
[TBL] [Abstract][Full Text] [Related]
28. Pygenic Acid A (PA) Sensitizes Metastatic Breast Cancer Cells to Anoikis and Inhibits Metastasis In Vivo.
Lim GE; Sung JY; Yu S; Kim Y; Shim J; Kim HJ; Cho ML; Lee JS; Kim YN
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33182770
[TBL] [Abstract][Full Text] [Related]
29. Selective inhibition of SCLC growth by the A12 anti-IGF-1R monoclonal antibody correlates with inhibition of Akt.
Yeh J; Litz J; Hauck P; Ludwig DL; Krystal GW
Lung Cancer; 2008 May; 60(2):166-74. PubMed ID: 18006183
[TBL] [Abstract][Full Text] [Related]
30. Fatty acid binding protein 5 promotes metastatic potential of triple negative breast cancer cells through enhancing epidermal growth factor receptor stability.
Powell CA; Nasser MW; Zhao H; Wochna JC; Zhang X; Shapiro C; Shilo K; Ganju RK
Oncotarget; 2015 Mar; 6(8):6373-85. PubMed ID: 25779666
[TBL] [Abstract][Full Text] [Related]
31. The Gαh-PLCδ1 signaling axis drives metastatic progression in triple-negative breast cancer.
Huang SP; Liu PY; Kuo CJ; Chen CL; Lee WJ; Tsai YH; Lin YF
J Hematol Oncol; 2017 Jun; 10(1):114. PubMed ID: 28576130
[TBL] [Abstract][Full Text] [Related]
32. Role of AMPK and Akt in triple negative breast cancer lung colonization.
Johnson J; Chow Z; Lee E; Weiss HL; Evers BM; Rychahou P
Neoplasia; 2021 Apr; 23(4):429-438. PubMed ID: 33839456
[TBL] [Abstract][Full Text] [Related]
33.
Solomon VR; Alizadeh E; Bernhard W; Hartimath SV; Hill W; Chekol R; Barreto KM; Geyer CR; Fonge H
Mol Pharm; 2019 Dec; 16(12):4807-4816. PubMed ID: 31518138
[TBL] [Abstract][Full Text] [Related]
34. Characterization of triple-negative breast cancer preclinical models provides functional evidence of metastatic progression.
Arroyo-Crespo JJ; Armiñán A; Charbonnier D; Deladriere C; Palomino-Schätzlein M; Lamas-Domingo R; Forteza J; Pineda-Lucena A; Vicent MJ
Int J Cancer; 2019 Oct; 145(8):2267-2281. PubMed ID: 30860605
[TBL] [Abstract][Full Text] [Related]
35. Replenishment of myeloid-derived suppressor cells (MDSCs) overrides CR-mediated protection against tumor growth in a murine model of triple-negative breast cancer.
Pomatto-Watson LCD; Bodogai M; Carpenter M; Chowdhury D; Krishna P; Ng S; Bosompra O; Kato J; Wong S; Reyes-Sepulveda C; Bernier M; Price NL; Biragyn A; de Cabo R
Geroscience; 2022 Oct; 44(5):2471-2490. PubMed ID: 35996062
[TBL] [Abstract][Full Text] [Related]
36. In vivo magnetic resonance imaging investigating the development of experimental brain metastases due to triple negative breast cancer.
Hamilton AM; Foster PJ
Clin Exp Metastasis; 2017 Feb; 34(2):133-140. PubMed ID: 28108861
[TBL] [Abstract][Full Text] [Related]
37. Molecular biomarkers for prediction of response to treatment and survival in triple negative breast cancer patients from Egypt.
Bahnassy A; Mohanad M; Ismail MF; Shaarawy S; El-Bastawisy A; Zekri AR
Exp Mol Pathol; 2015 Oct; 99(2):303-11. PubMed ID: 26232605
[TBL] [Abstract][Full Text] [Related]
38. Id1-induced IGF-II and its autocrine/endocrine promotion of esophageal cancer progression and chemoresistance--implications for IGF-II and IGF-IR-targeted therapy.
Li B; Tsao SW; Chan KW; Ludwig DL; Novosyadlyy R; Li YY; He QY; Cheung AL
Clin Cancer Res; 2014 May; 20(10):2651-62. PubMed ID: 24599933
[TBL] [Abstract][Full Text] [Related]
39. Genetic blockade of the insulin-like growth factor-I receptor: a promising strategy for human pancreatic cancer.
Min Y; Adachi Y; Yamamoto H; Ito H; Itoh F; Lee CT; Nadaf S; Carbone DP; Imai K
Cancer Res; 2003 Oct; 63(19):6432-41. PubMed ID: 14559833
[TBL] [Abstract][Full Text] [Related]
40. Combining losartan with radiotherapy increases tumor control and inhibits lung metastases from a HER2/neu-positive orthotopic breast cancer model.
Li W; Li S; Chen IX; Liu Y; Ramjiawan RR; Leung CH; Gerweck LE; Fukumura D; Loeffler JS; Jain RK; Duda DG; Huang P
Radiat Oncol; 2021 Mar; 16(1):48. PubMed ID: 33663521
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
